DNA FY 2024 Earnings — Ginkgo Bioworks Holdings, Inc. Revenue & Financial Results | Market Cap Arena

DNAGinkgo Bioworks Holdings, Inc.

$418M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$227M-9.7% YoY

Gross Profit

$188M83.0% margin

Operating Income

-$560M-246.5% margin

Net Income

-$547M-240.9% margin

EPS (Diluted)

$-10.54

Cash Flow

Operating Cash Flow

-$320M

Free Cash Flow

-$382M

Stock-Based Comp.

$112M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$661M

Stockholders' Equity

$716M

Cash & Equivalents

$562M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$227M	$251M	-9.7%
Gross Profit	$188M	$197M	-4.5%
Operating Income	-$560M	-$864M	+35.2%
Net Income	-$547M	-$893M	+38.7%